# Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

> **NCT03977584** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 114 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Crenezumab
- **DRUG:** Placebo
- **OTHER:** [^18F]GTP1

## Key facts

- **NCT ID:** NCT03977584
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-10
- **Primary completion:** 2022-04-19
- **Final completion:** 2022-04-19
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2024-03-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03977584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03977584, "Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03977584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*